Journal of Shanghai Jiao Tong University (Medical Science) >

2023 , Vol. 43 >Issue 12: 1562 - 1568

DOI: https://doi.org/10.3969/j.issn.1674-8115.2023.12.012

Review

Research progress in the treatment of bladder cancer based on nanotechnology

  • Chenkai YANG ,
  • Wei LI ,
  • Xiangqian CAO ,
  • Lei HE ,
  • Shengzhou LI ,
  • Bing SHEN
Expand
  • 1.Department of Urology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
    2.Department of Nanomedicine, Naval Medical University, Shanghai Key Laboratory of Cell Engineering, Shanghai 200433, China
    3.School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai 200093, China
SHEN Bing, E-mail: urodrshenbing@shsmu.edu.cn.

Received date: 2023-08-10

  Accepted date: 2023-11-20

  Online published: 2024-02-01

Supported by

National Natural Science Foundation of China(82072821);Shanghai Songjiang Municipal Natural Science Foundation(20SJKJGG250)

Fold

Abstract

Bladder cancer is the most common malignant tumor in the urinary system. Currently, the clinical treatment options for bladder cancer mainly include surgery, chemotherapy, radiotherapy, immunotherapy, targeted therapy, photodynamic therapy, combination therapy, etc. The conventional treatment and administration strategies for bladder cancer primarily depend on the tumor stage and the extent of metastasis. However, in the process of non-surgical treatment, drugs lack specificity and targeting. Once the dosage is improperly controlled, drugs will damage normal cells when attacking cancer cells, which will lead to poor efficacy and multiple side effects. Nanomedicine is an emerging interdisciplinary field that utilizes nanomaterials and technologies in nanomedicine to provide disruptive technologies for traditional treatments, with advantages such as targeted delivery and high efficiency with low toxicity. Many nanotechnologies have become hot topics in clinical research in the field of medicine. Functionalized nanoparticles can actively or passively target specific cells within target organs, such as bladder cancer cells, by altering their surface properties, thereby enhancing drug delivery precision, reducing damage to normal cells, and improving treatment efficacy. This article provides an overview of the progress in classical and novel treatment approaches to bladder cancer, with a particular focus on the potential applications and future development directions of nanotechnology in the treatment of bladder cancer, providing important reference for personalized therapy and clinical translation in bladder cancer.

Key words： bladder cancer; nanotechnology; targeting effect; treatment

Cite this article

Chenkai YANG , Wei LI , Xiangqian CAO , Lei HE , Shengzhou LI , Bing SHEN . Research progress in the treatment of bladder cancer based on nanotechnology[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023 , 43(12) : 1562 -1568 . DOI: 10.3969/j.issn.1674-8115.2023.12.012

References

1 SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
2 TEOH J Y, HUANG J, KO W Y, et al. Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita[J]. Eur Urol, 2020, 78(6): 893-906.
3 SIEGEL R L, MILLER K D, WAGLE N S, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48.
4 CHEN W. Cancer statistics: updated cancer burden in China[J]. Chin J Cancer Res, 2015, 27(1): 1.
5 AMIN H A A, KOBAISI M H, SAMIR R M. Schistosomiasis and bladder cancer in Egypt: truths and myths[J]. Open Access Maced J Med Sci, 2019, 7(23): 4023-4029.
6 MOCH H, CUBILLA A L, HUMPHREY P A, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours[J]. Eur Urol, 2016, 70(1): 93-105.
7 BOUCHELOUCHE K. Diagnostic applications of nuclear medicine: kidney and bladder cancer[M/OL]//STRAUSS H W, MARIANI G, VOLTERRANI D, et al. Nuclear Oncology. Cham: Springer International Publishing, 2017: 839-881[2023-08-09]. https://doi.org/10.1007/978-3-319-26236-9_20.
8 BARTON M K. High morbidity and mortality found for high-risk, non-muscle-invasive bladder cancer[J]. CA Cancer J Clin, 2013, 63(6): 371-372.
9 BABJUK M, B?HLE A, BURGER M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016[J]. Eur Urol, 2017, 71(3): 447-461.
10 LIU B, GAO X, HAN B, et al. Mouse model to explore the therapeutic effect of nano-doxorubicin drug delivery system on bladder cancer[J]. J Nanosci Nanotechnol, 2021, 21(2): 914-920.
11 DOHERTY A P, TRENDELL-SMITH N, STIRLING R, et al. Perivesical fat necrosis after adjuvant intravesical chemotherapy[J]. BJU Int, 1999, 83(4): 420-423.
12 MESSING E M, TANGEN C M, LERNER S P, et al. Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial[J]. JAMA, 2018, 319(18): 1880-1888.
13 LAMM D L, BLUMENSTEIN B A, CRISSMAN J D, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study[J]. J Urol, 2000, 163(4): 1124-1129.
14 PETTENATI C, INGERSOLL M A. Mechanisms of BCG immunotherapy and its outlook for bladder cancer[J]. Nat Rev Urol, 2018, 15(10): 615-625.
15 LENIS A T, LEC P M, CHAMIE K, et al. Bladder cancer: a review[J]. JAMA, 2020, 324(19): 1980-1991.
16 WITJES J A, BABJUK M, BELLMUNT J, et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer: an international collaborative multistakeholder effort: under the auspices of the EAU-ESMO guidelines committees[J]. Eur Urol, 2020, 77(2): 223-250.
17 ALFRED W J, MAX B H, CARRIóN A, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines[J]. Eur Urol, 2024, 85(1): 17-31.
18 PLOUSSARD G, DANESHMAND S, EFSTATHIOU J A, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review[J]. Eur Urol, 2014, 66(1): 120-137.
19 CANIL C. Bladder cancer[M/OL]//ENNA S J, BYLUND D B. xPharm: the comprehensive pharmacology reference. Amsterdam: Elsevier, 2007: 1-4[2023-08-09]. https://doi.org/10.1016/B978-008055232-3.60818-9.
20 BAJORIN D F, WITJES J A, GSCHWEND J E, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma[J]. N Engl J Med, 2021, 384(22): 2102-2114.
21 SARFRAZ M, QAMAR S, REHMAN M U, et al. Nano-formulation based intravesical drug delivery systems: an overview of versatile approaches to improve urinary bladder diseases[J]. Pharmaceutics, 2022, 14(9): 1909.
22 VAN DER HEIJDEN M S, LORIOT Y, DURáN I, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma: a long-term overall survival and safety update from the phase 3 IMvigor211 clinical trial[J]. Eur Urol, 2021, 80(1): 7-11.
23 DONIN N M, LENIS A T, HOLDEN S, et al. Immunotherapy for the treatment of urothelial carcinoma[J]. J Urol, 2017, 197(1): 14-22.
24 LI Q, LIU Y, HUANG Z, et al. Triggering immune system with nanomaterials for cancer immunotherapy[J]. Front Bioeng Biotechnol, 2022, 10: 878524.
25 SHARMA P, RETZ M, SIEFKER-RADTKE A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2017, 18(3): 312-322.
26 POWLES T, O'DONNELL P H, MASSARD C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study[J]. JAMA Oncol, 2017, 3(9): e172411.
27 APOLO A B, INFANTE J R, BALMANOUKIAN A, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ⅰb study[J]. J Clin Oncol, 2017, 35(19): 2117-2124.
28 PREDINA J, ERUSLANOV E, JUDY B, et al. Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery[J]. Proc Natl Acad Sci U S A, 2013, 110(5): E415-E424.
29 MILLING L, ZHANG Y, IRVINE D J. Delivering safer immunotherapies for cancer[J]. Adv Drug Deliv Rev, 2017, 114: 79-101.
30 LORIOT Y, NECCHI A, PARK S H, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma[J]. N Engl J Med, 2019, 381(4): 338-348.
31 ROBINSON B D, VLACHOSTERGIOS P J, BHINDER B, et al. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling[J]. Nat Commun, 2019, 10(1): 2977.
32 SHENG X, YAN X, WANG L, et al. Open-label, multicenter, phase Ⅱ study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma[J]. Clin Cancer Res, 2021, 27(1): 43-51.
33 SARFATY M, ROSENBERG J E. Antibody-drug conjugates in urothelial carcinomas[J]. Curr Oncol Rep, 2020, 22(2): 13.
34 ROSENBERG J E, O'DONNELL P H, BALAR A V, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy[J]. J Clin Oncol, 2019, 37(29): 2592-2600.
35 HU H, FENG W, QIAN X, et al. Emerging nanomedicine-enabled/enhanced nanodynamic therapies beyond traditional photodynamics[J]. Adv Mater, 2021, 33(12): e2005062.
36 INOUE K. 5-Aminolevulinic acid-mediated photodynamic therapy for bladder cancer[J]. Int J Urol, 2017, 24(2): 97-101.
37 DIAMOND I, MCDONAGH A, WILSON C, et al. Photodynamic therapy of malignant tumours[J]. Lancet, 1972, 300(7788): 1175-1177.
38 LEE J Y, DIAZ R R, CHO K S, et al. Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy[J]. J Urol, 2013, 190(4): 1192-1199.
39 XIONG W, QI L, JIANG N, et al. Metformin liposome-mediated PD-L1 downregulation for amplifying the photodynamic immunotherapy efficacy[J]. ACS Appl Mater Interfaces, 2021, 13(7): 8026-8041.
40 WANG L, YANG D, LV J Y, et al. Application of carbon nanoparticles in lymph node dissection and parathyroid protection during thyroid cancer surgeries: a systematic review and meta-analysis[J]. Onco Targets Ther, 2017, 10: 1247-1260.
41 SHI J J, KANTOFF P W, WOOSTER R, et al. Cancer nanomedicine: progress, challenges and opportunities[J]. Nat Rev Cancer, 2017, 17(1): 20-37.
42 MATSUMURA Y, MAEDA H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs[J]. Cancer Res, 1986, 46(12 Pt 1): 6387-6392.
43 MI P, CABRAL H, KATAOKA K. Ligand-installed nanocarriers toward precision therapy[J]. Adv Mater, 2020, 32(13): e1902604.
44 GERLOWSKI L E, JAIN R K. Microvascular permeability of normal and neoplastic tissues[J]. Microvasc Res, 1986, 31(3): 288-305.
45 KULKARNI A, CHANDRASEKAR V, NATARAJAN S K, et al. A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer[J]. Nat Biomed Eng, 2018, 2(8): 589-599.
46 DE LA TORRE P, PéREZ-LORENZO M J, ALCáZAR-GARRIDO á, et al. Cell-based nanoparticles delivery systems for targeted cancer therapy: lessons from anti-angiogenesis treatments[J]. Molecules, 2020, 25(3): 715.
47 LI X, CHEN L, LUAN S, et al. The development and progress of nanomedicine for esophageal cancer diagnosis and treatment[J]. Semin Cancer Biol, 2022, 86(Pt 2): 873-885.
48 XU X, LIU K, JIAO B, et al. Mucoadhesive nanoparticles based on ROS activated gambogic acid prodrug for safe and efficient intravesical instillation chemotherapy of bladder cancer[J]. J Control Release, 2020, 324: 493-504.
49 ZHENG B, LIU Z, WANG H, et al. R11 modified tumor cell membrane nanovesicle-camouflaged nanoparticles with enhanced targeting and mucus-penetrating efficiency for intravesical chemotherapy for bladder cancer[J]. J Control Release, 2022, 351: 834-846.
50 MULLAPUDI S S, RAHMAT J N, MAHENDRAN R, et al. Tumor-targeting albumin nanoparticles as an efficacious drug delivery system and potential diagnostic tool in non-muscle-invasive bladder cancer therapy[J]. Nanomedicine, 2022, 46: 102600.
51 AKGüL A, AHMED N, RAZA A, et al. A fractal fractional model for cervical cancer due to human papillomavirus infection[J]. Fractals, 2021, 29(5): 2140015.
52 SPRANGER S, GAJEWSKI T F. Impact of oncogenic pathways on evasion of antitumour immune responses[J]. Nat Rev Cancer, 2018, 18(3): 139-147.
53 SHARMA P, HU-LIESKOVAN S, WARGO J A, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy[J]. Cell, 2017, 168(4): 707-723.
54 KLEMM F, MAAS R R, BOWMAN R L, et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells[J]. Cell, 2020, 181(7): 1643-1660.e17.
55 TERáN-NAVARRO H, ZEOLI A, SALINES-CUEVAS D, et al. Gold glyconanoparticles combined with 91?99 peptide of the bacterial toxin, listeriolysin O, are efficient immunotherapies in experimental bladder tumors[J]. Cancers (Basel), 2022, 14(10): 2413.
56 HUNTER B A, EUSTACE A, IRLAM J J, et al. Expression of hypoxia-inducible factor-1α predicts benefit from hypoxia modification in invasive bladder cancer[J]. Br J Cancer, 2014, 111(3): 437-443.
57 MARTINEZ-OUTSCHOORN U E, LIN Z, TRIMMER C, et al. Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: implications for PET imaging of human tumors[J]. Cell Cycle, 2011, 10(15): 2504-2520.
58 LIN T, ZHAO X, ZHAO S, et al. O2-generating MnO2 nanoparticles for enhanced photodynamic therapy of bladder cancer by ameliorating hypoxia[J]. Theranostics, 2018, 8(4): 990-1004.
59 YU C, ZHANG Y, WANG N, et al. Treatment of bladder cancer by geoinspired synthetic chrysotile nanocarrier-delivered circPRMT5 siRNA[J]. Biomater Res, 2022, 26(1): 6.
60 CHEN Y, GAO D Y, HUANG L. In vivo delivery of miRNAs for cancer therapy: challenges and strategies[J]. Adv Drug Deliv Rev, 2015, 81: 128-141.
61 SHEN H, SUN T, FERRARI M. Nanovector delivery of siRNA for cancer therapy[J]. Cancer Gene Ther, 2012, 19(6): 367-373.
62 SHAHIDI M, ABAZARI O, DAYATI P, et al. Multicomponent siRNA/miRNA-loaded modified mesoporous silica nanoparticles targeted bladder cancer for a highly effective combination therapy[J]. Front Bioeng Biotechnol, 2022, 10: 949704.
63 ZHANG L, WAN S S, LI C X, et al. An adenosine triphosphate-responsive autocatalytic Fenton nanoparticle for tumor ablation with self-supplied H2O2 and acceleration of Fe3+/Fe2+ conversion[J]. Nano Lett, 2018, 18(12): 7609-7618.
64 TANG Z, ZHANG H, LIU Y, et al. Antiferromagnetic pyrite as the tumor microenvironment-mediated nanoplatform for self-enhanced tumor imaging and therapy[J]. Adv Mater, 2017, 29(47). doi: 10.1002/adma.201701683.
65 CHEN W H, YU K J, JHOU J W, et al. Glucose/glutathione Co-triggered tumor hypoxia relief and chemodynamic therapy to enhance photothermal therapy in bladder cancer[J]. ACS Appl Bio Mater, 2021, 4(10): 7485-7496.
Options
Outlines

/

〈 〉